The MATRx Titration System
To be truly disruptive, Zephyr is now on
the path to:
• Reduce the overall cost of delivering
the MATRx test,
• Make the MATRx capability more accessible, and
• Change the business model to provide
structural cost advantage to our healthcare system.
What drives Dr. Remmers and the Zephyr
team is better health, better quality of life and
the opportunity to make a real difference.
What drives Dr. Remmers and the Zephyr team is better health, better quality
of life and the opportunity to make a
real difference. By creating new technology, Dr. Remmers and the team of 32
engineers, scientists and business professionals at Zephyr are changing sleep
medicine.
Dr. Remmers has been around treating
OSA for decades and despite billions
of dollars spent, is frankly disappointed with our ability to treat this illness.
There are two primary reasons for our
poor performance:
i) CPAP, our treatment of choice, isn’t
well tolerated or accepted and
ii) OSA inclusion rates are overwhelming our healthcare system due to an aging and increasingly obese population.
This is no longer an illness/treatment
issue, this is now a global healthcare
problem. 5,000 sleep centers in the US
are no longer capable of dealing with
the sheer scale of this problem. We need
alternative treatments, higher effectiveness and better access.
Since the release of MATRx, and after
four years of hard work, three clinical
trials, a little bit of luck and buckets of
tenacity, creativity and commitment –
Zephyr is getting ready to release the
next version of the MATRx – MATRx for
the home…stay tuned!
The MATRx Technology
In 2012, Zephyr brought Dr. Remmers’
in-lab MATRx technology to market.
After prescribing a MATRx test, a sleep
physician determines two key pieces of
information:
STOP BY OUR AADSM BOOTH #112
i) Will the patient’s OSA be treated with
an oral appliance and if so
ii) What is the target protrusive position?
Meet Dr. Remmers and the Zephyr team, and demo our MATRx
technology!
MATRx is a patient SELECTION tool. By
selecting patients we know will respond
to OAT, in advance, we increase oral appliance efficacy. The oft-maligned OAT
is now reinvigorated by being “prescribable” by a sleep physician with the
confidence in its treatment outcome.
MATRx technology puts OAT efficacy on
par with CPAP efficacy and with higher
adherence, should move the needle on
therapy effectiveness.
For more information contact
Jodi Jacks, Director, Sales and
Distribution
Mobile: 614-316-5420 | Email:
[email protected]